This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnrd4035/MediaObjects/41573_2013_Article_BFnrd4035_Fig1_HTML.jpg)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fnrd4035/MediaObjects/41573_2013_Article_BFnrd4035_Fig2_HTML.jpg)
Acknowledgements
The authors gratefully acknowledge the contributions of M. Herant, G. Hersch and B. Howard to this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors of this article are employees of The Boston Consulting Group (BCG), a management consultancy that works with the world's leading biopharmaceutical companies on R&D productivity issues. The research for this specific article was funded by BCG's Health Care practice.
Supplementary information
Supplementary Table S1
(PDF 882 kb)
Supplementary Box S2
Dataset and details of analysis (PDF 475 kb)
PowerPoint slides
Rights and permissions
About this article
Cite this article
Schulze, U., Ringel, M. What matters most in commercial success: first-in-class or best-in-class?. Nat Rev Drug Discov 12, 419–420 (2013). https://doi.org/10.1038/nrd4035
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4035
This article is cited by
-
Drug launch curves in the modern era
Nature Reviews Drug Discovery (2017)